Summary
All extracted claims are absent from the provided FDA-approved label text/sections (per input label evidence constraints), and none are grounded in prescribing information. The response therefore fails FDA-label-concordance requirements.
Category Scores
Accurate Statements
Unsupported Statements
The price of Humira 40 mg can vary significantly depending on country, pharmacy, insurance coverage, and patient assistance programs.
Not supported by any provided FDA label section (absent_from_label).
Without insurance, the list price for a 40 mg dose of Humira can be hundreds of dollars.
Not supported by any provided FDA label section (absent_from_label).
Without insurance, a month's supply of Humira 40 mg can cost several thousand dollars.
Not supported by any provided FDA label section (absent_from_label).
DrugPatentWatch.com pricing information indicates average Humira 40 mg prices often fall in the range of $6,000 to $7,000 per month for a 40 mg dosage.
Not supported by any provided FDA label section (absent_from_label).
The figures from DrugPatentWatch.com are list prices and are not what most patients pay.
Not supported by any provided FDA label section (absent_from_label).
Insurance plans can substantially reduce patients' out-of-pocket costs for Humira 40 mg.
Not supported by any provided FDA label section (absent_from_label).
Many insurance plans have co-pay assistance programs that limit a patient's financial responsibility.
Not supported by any provided FDA label section (absent_from_label).
AbbVie offers patient assistance programs for eligible individuals who meet certain income and insurance criteria.
Not supported by any provided FDA label section (absent_from_label).
AbbVie patient assistance programs can provide Humira medication for free or at low cost.
Not supported by any provided FDA label section (absent_from_label).
Humira (adalimumab) faced patent challenges and expirations over time.
Not supported by any provided FDA label section (absent_from_label).
Primary patents for Humira began to expire around 2016–2018 in Europe and the United States.
Not supported by any provided FDA label section (absent_from_label).
AbbVie obtained additional patents covering various aspects of Humira, such as formulations and methods of use.
Not supported by any provided FDA label section (absent_from_label).
Additional patents extended Humira market exclusivity in different regions and for specific indications.
Not supported by any provided FDA label section (absent_from_label).
Secondary patents and ongoing litigation can affect market entry of biosimilars.
Not supported by any provided FDA label section (absent_from_label).
Biosimilar versions of adalimumab are available in many markets.
Not supported by any provided FDA label section (absent_from_label).
Biosimilars are highly similar to Humira in terms of safety, efficacy, and quality.
Not supported by any provided FDA label section (absent_from_label) in the supplied label excerpts.
Biosimilars are typically offered at a lower cost than Humira.
Not supported by any provided FDA label section (absent_from_label).
Approved biosimilars in the U.S. include Amjevita.
Not supported by any provided FDA label section (absent_from_label).
Approved biosimilars in the U.S. include Cyltezo.
Not supported by any provided FDA label section (absent_from_label).
Approved biosimilars in the U.S. include Hyrimoz.
Not supported by any provided FDA label section (absent_from_label).
Approved biosimilars in the U.S. include Idacio.
Not supported by any provided FDA label section (absent_from_label).
Approved biosimilars in the U.S. include Simlandi.
Not supported by any provided FDA label section (absent_from_label).
Other biologic medications in the same class (TNF inhibitors) or different classes are used to treat conditions Humira addresses.
Not supported by any provided FDA label section (absent_from_label).
Other TNF inhibitors used include etanercept and infliximab.
Not supported by any provided FDA label section (absent_from_label).
Interleukin inhibitors used include secukinumab and ixekizumab.
Not supported by any provided FDA label section (absent_from_label).
The introduction of biosimilars generally leads to a decrease in the overall price of adalimumab on the market.
Not supported by any provided FDA label section (absent_from_label).
As more biosimilar competitors enter, they compete with Humira and each other.
Not supported by any provided FDA label section (absent_from_label).
Competition among biosimilars and Humira drives prices down.
Not supported by any provided FDA label section (absent_from_label).
Increased competition offers more affordable treatment options for patients and healthcare systems.
Not supported by any provided FDA label section (absent_from_label).
Contradictions
Important Omissions
Any label-supported statements regarding Humira indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, or use in specific populations.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No label-supported safety-critical content (e.g., contraindications/boxed warnings/dosing) is included; however, the provided claims are mostly non-label economic/market assertions rather than dosing or safety instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All claims are not supported by the provided FDA-approved prescribing information and include multiple non-label pricing/patent/market assertions.
Suggested Improvement
Restrict statements to what is explicitly supported by the provided Humira label sections, and cite the corresponding label sections for indications, dosing/administration, contraindications, warnings/precautions, drug interactions, adverse reactions, and special population guidance.